From ChatGPT
The newest dengue vaccine available in Thailand is Qdenga®, developed by Takeda Pharmaceuticals. Approved in 2023, Qdenga® is a live-attenuated recombinant vaccine designed to protect against all four serotypes of the dengue virus. It is suitable for individuals aged 4 to 60 years, regardless of prior dengue infection, eliminating the need for pre-vaccination screening.
Clinical studies have demonstrated that Qdenga® offers approximately 80.2% protection against dengue fever and can reduce hospitalization rates by up to 90.4%. The vaccination regimen consists of two doses administered three months apart.
Prior to Qdenga®, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur, was the only dengue vaccine available in Thailand since its approval in 2017. Dengvaxia® is recommended only for individuals aged 6 to 45 years who have had a previous dengue infection, due to safety concerns related to antibody-dependent enhancement in dengue-naive individuals.
For more information or to receive the Qdenga® vaccine, you can contact local healthcare providers such as Bangkok Hospital, which offers the new dengue vaccine.